Trastuzumab (Herceptin), a monoclonal antibody, is used to target the extracellular domain of the HER2 protein in HER2-positive breast cancer patients and has been shown to increase survival at early and late stages of breast cancer [7]. This evidence concerns the gene ERBB2 and breast carcinoma.